Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
Zhe Yang(Shandong Provincial Hospital), Caicun Zhou(Tongji University), Qiuxiang Ou(Genesee Community College), Yi Xiang(Ruijin Hospital), Nong Yang(Central South University), Hua Bao, Xiaonan Wang(Tongji University), Tao Jiang(Tongji University), Xiaoling Tong(SUNY Geneseo), Yunpeng Liu(Shenyang Institute of Automation), Yang Shao(Sanya University), Yan Wang(National Institute of Biological Sciences, Beijing), Xue Wu(Hangzhou Normal University)
Cited by 551
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k